BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Visentin A, Imbergamo S, Scomazzon E, Pravato S, Frezzato F, Bonaldi L, Pizzi M, Vio S, Gregianin M, Burei M, Facco M, Semenzato G, Piazza F, Trentin L.
Visentin A, et al. Among authors: pizzi m.
Br J Haematol. 2019 Apr;185(1):193-197. doi: 10.1111/bjh.15440. Epub 2018 Jul 5.
Br J Haematol. 2019.
PMID: 29974955
Free article.
No abstract available.